Cargando…

The effectiveness of atrial fibrillation special clinic on oral anticoagulant use for high risk atrial fibrillation patients managed in the community

BACKGROUND: Service gaps exist in oral anticoagulant (OAC) use among patients with atrial fibrillation (AF) in primary care. The purpose of this study was to explore the clinical effectiveness of a community dwelling Atrial Fibrillation Special Clinic (AFSC) run by primary care physicians by evaluat...

Descripción completa

Detalles Bibliográficos
Autores principales: Lau, Ka Man, Leung, To Fung, Li, Yim Chu, Chen, Catherine Xiao Rui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9926793/
https://www.ncbi.nlm.nih.gov/pubmed/36788489
http://dx.doi.org/10.1186/s12875-023-02004-w
_version_ 1784888351864651776
author Lau, Ka Man
Leung, To Fung
Li, Yim Chu
Chen, Catherine Xiao Rui
author_facet Lau, Ka Man
Leung, To Fung
Li, Yim Chu
Chen, Catherine Xiao Rui
author_sort Lau, Ka Man
collection PubMed
description BACKGROUND: Service gaps exist in oral anticoagulant (OAC) use among patients with atrial fibrillation (AF) in primary care. The purpose of this study was to explore the clinical effectiveness of a community dwelling Atrial Fibrillation Special Clinic (AFSC) run by primary care physicians by evaluating its impact on OAC use and the control of modifiable cardiovascular disease (CVD) risk factors in high risk AF patients. METHOD: Quasi-experimental study was conducted in AFSC run by public primary care physicians in Hong Kong. Study subjects were high risk AF patients with CHA(2)DS(2)-VASc scores ≥ 2, who had been followed up (FU) at AFSC for at least one year from 01 August, 2019 to 31 October, 2020. OAC usage and modifiable CVD risk factor control were compared before and after one year of FU at AFSC. Drug-related adverse events, emergency attendance or hospitalisation episodes, survival and mortality rates after one year FU at AFSC were also reviewed. RESULTS: Among the 299 high risk AF patients included in the study, significant increase in OAC use was observed from 58.5% at baseline to 82.6% after one year FU in AFSC (P < 0.001). Concerning CVD risk factor control, the average diastolic blood pressure level was significantly reduced (P = 0.009) and the satisfactory blood pressure control rate in non-diabetic patients was markedly improved after one year FU (P = 0.049). However, the average HbA1c and LDL-c levels remained static. The annual incidence rate of ischaemic stroke/systemic embolism was 0.4%, intra-cranial haemorrhage was 0.4%, major bleeding episode was 3.2% and all-cause mortality was 4.3%, all of which were comparable to reports in the literature. CONCLUSION: AFSC is effective in enhancing OAC use and maintaining optimal modifiable CVD risk factor control among high risk AF patients managed in primary care setting, and therefore may reduce AF-associated morbidity and mortality in the long run.
format Online
Article
Text
id pubmed-9926793
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-99267932023-02-15 The effectiveness of atrial fibrillation special clinic on oral anticoagulant use for high risk atrial fibrillation patients managed in the community Lau, Ka Man Leung, To Fung Li, Yim Chu Chen, Catherine Xiao Rui BMC Prim Care Research BACKGROUND: Service gaps exist in oral anticoagulant (OAC) use among patients with atrial fibrillation (AF) in primary care. The purpose of this study was to explore the clinical effectiveness of a community dwelling Atrial Fibrillation Special Clinic (AFSC) run by primary care physicians by evaluating its impact on OAC use and the control of modifiable cardiovascular disease (CVD) risk factors in high risk AF patients. METHOD: Quasi-experimental study was conducted in AFSC run by public primary care physicians in Hong Kong. Study subjects were high risk AF patients with CHA(2)DS(2)-VASc scores ≥ 2, who had been followed up (FU) at AFSC for at least one year from 01 August, 2019 to 31 October, 2020. OAC usage and modifiable CVD risk factor control were compared before and after one year of FU at AFSC. Drug-related adverse events, emergency attendance or hospitalisation episodes, survival and mortality rates after one year FU at AFSC were also reviewed. RESULTS: Among the 299 high risk AF patients included in the study, significant increase in OAC use was observed from 58.5% at baseline to 82.6% after one year FU in AFSC (P < 0.001). Concerning CVD risk factor control, the average diastolic blood pressure level was significantly reduced (P = 0.009) and the satisfactory blood pressure control rate in non-diabetic patients was markedly improved after one year FU (P = 0.049). However, the average HbA1c and LDL-c levels remained static. The annual incidence rate of ischaemic stroke/systemic embolism was 0.4%, intra-cranial haemorrhage was 0.4%, major bleeding episode was 3.2% and all-cause mortality was 4.3%, all of which were comparable to reports in the literature. CONCLUSION: AFSC is effective in enhancing OAC use and maintaining optimal modifiable CVD risk factor control among high risk AF patients managed in primary care setting, and therefore may reduce AF-associated morbidity and mortality in the long run. BioMed Central 2023-02-14 /pmc/articles/PMC9926793/ /pubmed/36788489 http://dx.doi.org/10.1186/s12875-023-02004-w Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Lau, Ka Man
Leung, To Fung
Li, Yim Chu
Chen, Catherine Xiao Rui
The effectiveness of atrial fibrillation special clinic on oral anticoagulant use for high risk atrial fibrillation patients managed in the community
title The effectiveness of atrial fibrillation special clinic on oral anticoagulant use for high risk atrial fibrillation patients managed in the community
title_full The effectiveness of atrial fibrillation special clinic on oral anticoagulant use for high risk atrial fibrillation patients managed in the community
title_fullStr The effectiveness of atrial fibrillation special clinic on oral anticoagulant use for high risk atrial fibrillation patients managed in the community
title_full_unstemmed The effectiveness of atrial fibrillation special clinic on oral anticoagulant use for high risk atrial fibrillation patients managed in the community
title_short The effectiveness of atrial fibrillation special clinic on oral anticoagulant use for high risk atrial fibrillation patients managed in the community
title_sort effectiveness of atrial fibrillation special clinic on oral anticoagulant use for high risk atrial fibrillation patients managed in the community
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9926793/
https://www.ncbi.nlm.nih.gov/pubmed/36788489
http://dx.doi.org/10.1186/s12875-023-02004-w
work_keys_str_mv AT laukaman theeffectivenessofatrialfibrillationspecialcliniconoralanticoagulantuseforhighriskatrialfibrillationpatientsmanagedinthecommunity
AT leungtofung theeffectivenessofatrialfibrillationspecialcliniconoralanticoagulantuseforhighriskatrialfibrillationpatientsmanagedinthecommunity
AT liyimchu theeffectivenessofatrialfibrillationspecialcliniconoralanticoagulantuseforhighriskatrialfibrillationpatientsmanagedinthecommunity
AT chencatherinexiaorui theeffectivenessofatrialfibrillationspecialcliniconoralanticoagulantuseforhighriskatrialfibrillationpatientsmanagedinthecommunity
AT laukaman effectivenessofatrialfibrillationspecialcliniconoralanticoagulantuseforhighriskatrialfibrillationpatientsmanagedinthecommunity
AT leungtofung effectivenessofatrialfibrillationspecialcliniconoralanticoagulantuseforhighriskatrialfibrillationpatientsmanagedinthecommunity
AT liyimchu effectivenessofatrialfibrillationspecialcliniconoralanticoagulantuseforhighriskatrialfibrillationpatientsmanagedinthecommunity
AT chencatherinexiaorui effectivenessofatrialfibrillationspecialcliniconoralanticoagulantuseforhighriskatrialfibrillationpatientsmanagedinthecommunity